• Citer

Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.

par Marechal, Raphaël ;Demols, Anne ;Gay, Frederick;De Maertelaer, Viviane ;Arvanitakis, Marianna ;Hendlisz, Alain ;Van Laethem, Jean-Luc
Référence Oncology, 73, 1-2, page (41-51)
Publication Publié, 2007

Article révisé par les pairs

• Détails
• Contenu

Résumé :

Gemcitabine monotherapy is the cornerstone of the treatment of patients suffering from advanced pancreatic cancer (PC). For a few years, new chemotherapeutic agents and combinations have been under validation. The use of such treatment makes it necessary to determine factors that could predict survival time.